Hyderabad, the new vaccine capital of India Apart from Covaxin and Sputnik V, companies based in the city are also involved in developing or manufacturing several other Covid-19 vaccines.
Jan 23, 2021
When a senior technical team from Russia’s health ministry descended on Hyderabad in November 2020, nobody knew that it was breaking an emerging oligopoly in the Indian market, quietly but decisively. The manufacturing of the Covid-19 vaccine wasn’t meant to be restricted to a few.
After auditing several facilities across the country, the Russian team chose three companies from Hyderabad, to undertake clinical trials for its Covid-19 vaccine, Sputnik V, in India and contract-manufacture the vaccine Dr Reddy’s Laboratories (DRL), Hetero Biopharma, and Virchow Biotech.
Updated Dec 21, 2020 | 14:22 IST
This southern city, already recognised as a global information technology destination, proved its prowess in the field of pharma and biotech and emerged as the vaccine capital of the world. Hyderabad: Vaccine capital of the world | Photo Credit: Representative Image
Amid the gloom caused by COVID-19, one sector which provided a ray of hope was life sciences and turning the challenge into an opportunity, Hyderabad fortified its position as a global force in the world of pharmaceuticals.
This southern city, already recognised as a global information technology destination, proved its prowess in the field of pharmaceuticals and biotechnology and emerged as the vaccine capital of the world.
Hyderabad: Vaccine capital of the world
Sun, Dec 20 2020 02:37:37 PM
By Mohammed Shafeeq
Hyderabad, Dec 20 (IANS): Amid the gloom caused by COVID-19, one sector which provided a ray of hope was life sciences and turning the challenge into an opportunity, Hyderabad fortified its position as a global force in the world of pharmaceuticals.
This southern city, already recognised as a global information technology destination, proved its prowess in the field of pharmaceuticals and biotechnology and emerged as the vaccine capital of the world.
Already known as the bulk drug capital of India, Hyderabad witnessed manufacturing of lifesaving COVID-19 drugs like Remdesivir, Hydroxychloroquine and Favipiravir by some of the top pharma companies based here.
Hyderabad: Amid the gloom caused by COVID-19, one sector which provided a ray of hope was life sciences and turning the challenge into an opportunity, Hyderabad fortified its position as a global force in the world of pharmaceuticals.
This southern city, already recognised as a global information technology destination, proved its prowess in the field of pharmaceuticals and biotechnology and emerged as the vaccine capital of the world.
Already known as the bulk drug capital of India, Hyderabad witnessed manufacturing of lifesaving COVID-19 drugs like Remdesivir, Hydroxychloroquine and Favipiravir by some of the top pharma companies based here.
This was followed by hectic efforts in the city to develop COVID-19 vaccine. In fact, Hyderabad has emerged as the nerve centre of all research and development activities in the country for COVID-19 vaccines and has even attracted international attention.
Hyderabad: Vaccine capital of the world
By
Mohammed Shafeeq ( IANS) |
Published on
Sun, Dec 20 2020 13:12 IST |
0 Views
Hyderabad, vaccine capital of the world Image Source: IANS News
Hyderabad, Dec 20 : Amid the gloom caused by COVID-19, one sector which provided a ray of hope was life sciences and turning the challenge into an opportunity, Hyderabad fortified its position as a global force in the world of pharmaceuticals.
This southern city, already recognised as a global information technology destination, proved its prowess in the field of pharmaceuticals and biotechnology and emerged as the vaccine capital of the world.
Already known as the bulk drug capital of India, Hyderabad witnessed manufacturing of lifesaving COVID-19 drugs like Remdesivir, Hydroxychloroquine and Favipiravir by some of the top pharma companies based here.